Huseyin Baran Ozdemir

Dr. Huseyin Baran Ozdemir


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2018 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
AKAyşe Kalkancı
Ayşe Kalkancı
KBKamil Bilgihan
Kamil Bilgihan
PGPınar Uyar Göçün
Pınar Uyar Göçün
BÖBetül Öğüt
Betül Öğüt
MEMerve Erdoğan
Merve Erdoğan

1 October 2019 in Turkish Journal of Ophthalmology
Verified
Journal Article
Closed access
MHMurat Hasanreisoglu
Murat Hasanreisoglu
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
KÖKaan Özkan
Kaan Özkan
MYMurat Yüksel
Murat Yüksel
ZAZeynep Aktaş
Zeynep Aktaş
GGGökhan Gürelik
Gökhan Gürelik
To evaluate the long-term results of intravitreal dexamethasone implant (DEX) for noninfectious uveitis. The study included 62 eyes of 44 patients treated with DEX implant due to noninfectious uveitis and followed up for at least a year. Best-corrected visual acuity (BCVA), central foveal thickness, intraocular pressure (IOP), vitreous haze score, indications, immunomodulatory therapy and steroid usage before/after injection, number of injections, and adverse events were analyzed retrospectively. Average follow-up was 20 months (range 12-64 months). The female/male ratio was 29/15. Mean age was 50 years (range 22-75 years). The most frequent uveitis etiologies were idiopathic (25 patients, 40.3%) and Behçet’s uveitis. (17 patients, 27.4%) The most common indication for DEX injection was cystoid macular edema together with resistant vitreous haze (26 eyes, 41.9%). Twenty-two eyes (30%) received more than one DEX injection. Mean BCVA was improved from 0.55 logMAR at baseline to 0.38, 0.32, and 0.35 after 1, 3, and 6 months, respectively (p<0.001 for each). Mean CFT was decreased from 386 μm at baseline to 288, 311, and 302 μm after 1, 3, and 6 months, respectively (p<0.001 for each). Mean IOP did not change significantly during follow-up. Five eyes (8%) received topical anti-glaucoma medication (IOP ≥25 mmHg). Eighteen (46%) of 39 phakic eyes underwent cataract surgery during follow-up. Similar efficacy of the DEX implant was observed in eyes that received multiple injections. Systemic immunomodulatory therapy did not change significantly during follow-up. Intravitreal DEX injection does not alter systemic immunomodulatory therapy, but may facilitate the management of noninfectious uveitis by suppressing local intraocular inflammation. Multiple injections yielded comparable visual and anatomical outcomes to single injections. Follow-up for ocular hypertension and cataract formation are important, especially in eyes receiving multiple injections.

27 September 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
POPinar Ozdal
Pinar Ozdal

19 April 2020 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
MŞMehmet Ali Şekeroğlu
Mehmet Ali Şekeroğlu

5 June 2025 in BMJ Open Ophthalmology
Verified
Journal Article
Open access
PDF file
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
SOSengul Ozdek
Sengul Ozdek
ZTZuhal Ozen Tunay
Zuhal Ozen Tunay
SBSadik Etka Bayramoglu
Sadik Etka Bayramoglu
ESEmine Alyamac Sukgen
Emine Alyamac Sukgen
OGon behalf of BIG-ROP Study Group
on behalf of BIG-ROP Study Group
Objective: This study evaluated the clinical characteristics and treatment outcomes of bigger premature infants treated for retinopathy of prematurity (ROP). Methods: A retrospective, multicentre study analysed data from 33 ROP centres in Türkiye. Infants with gestational ages (GA) of 32–37 weeks and birth weights (BW) >1500 g who required ROP treatment were included. Patient demographics, clinical details, treatments, responses and complications were recorded. Descriptive statistics were calculated after excluding cases with missing or erroneous data. Results: The study included 365 eyes of 365 infants. The average GA at birth was 33±1 weeks, with a mean BW of 1896±316 g. Of these, 83.6% had type 1 ROP, and 16.4% had aggressive ROP (A-ROP). Treatment-requiring ROP (TR-ROP) occurred at an average postmenstrual age of 39.0±4.6 weeks. Among 170 infants with TR-ROP at their first exam, 81.2% were screened at 4 weeks postpartum. Reactivation of ROP was observed in 5.4% of the primary laser photocoagulation (LPC) group and 23.9% of the primary anti-vascular endothelial growth factor (VEGF) group (p<0.001). Reactivation and progression to stage 4–5 were more frequent in A-ROP cases (p=0.012; p=0.008). The need for additional treatment was significantly higher in cases of A-ROP, zone 1 disease or stage 4–5 disease (p<0.001). Anti-VEGF therapy demonstrated superior single-treatment success rates in A-ROP eyes compared with laser LPC (85.7% vs 60%, p=0.03). Infants requiring additional treatments also had higher rates of respiratory distress syndrome (RDS), maternal premature rupture of membranes (PROM) and non-ophthalmological surgical interventions (p<0.05). Conclusion: Bigger premature infants in low and middle-income countries should be screened earlier than 4 weeks after birth. A-ROP, zone 1 disease and stage 4–5 disease have higher reactivation risks. Primary anti-VEGF therapy was associated with a greater need for retreatment. Maternal PROM, RDS and surgical interventions also increase retreatment risk. Limitations include retrospective design and lack of smaller preterm comparisons, potentially limiting generalisability.

1 May 2024 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
IGIhsan Gokhan Gurelik
Ihsan Gokhan Gurelik
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
BABurak Acar
Burak Acar